TargetMol

NC9 TG2 inhibitor

Product Code:
 
TAR-T28137
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T28137-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28137-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28137-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
NC9 is an irreversible inhibitor of transglutaminase 2 (TG2) and also inhibits Factor XIIIA (FXIIIA).
CAS:
1352090-52-8
Formula:
C35H47N5O8S
Molecular Weight:
697.85
Purity:
0.98
SMILES:
CN(C)c1cccc2c(cccc12)S(=O)(=O)NCCOCCOCCNC(=O)[C@H](CCCCNC(=O)C=C)NC(=O)OCc1ccccc1

References

1. TG2 inhibitor compounds and uses. By Keillor, Jeffrey W.; Akbar, Abdullah; Eckert, Richard L.; Fisher, Matthew; Johnson, Gail V. W. From PCT Int. Appl. (2017), WO 2017179018 A1 20171019. 2. Structure-?Activity Relationships of Potent, Targeted Covalent Inhibitors That Abolish Both the Transamidation and GTP Binding Activities of Human Tissue Transglutaminase. By Akbar, Abdullah; McNeil, Nicole M. R.; Albert, Marie R.; Ta, Viviane; Adhikary, Gautam; Bourgeois, Karine; Eckert, Richard L.; Keillor, Jeffrey W. From Journal of Medicinal Chemistry (2017), 60(18), 7910-7927. 3. Transamidase site-?targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival. By Kerr, C.; Szmacinski, H.; Fisher, M. L.; Nance, B.; Lakowicz, J. R.; Akbar, A.; Keillor, J. W.; Lok Wong, T.; Godoy-Ruiz, R.; Toth, E. A.; et al. From Oncogene (2017), 36(21), 2981-2990. 4. Plasma membrane factor XIIIA transglutaminase activity regulates osteoblast matrix secretion and deposition by affecting microtubule dynamics. By Al-Jallad, Hadil F.; Myneni, Vamsee D.; Piercy-Kotb, Sarah A.; Chabot, Nicolas; Mulani, Amina; Keillor, Jeffrey W.; Kaartinen, Mari T. From PLoS One (2011), 6(1), e15893.